ISRCTN70017204已完成未知
A multicentre, randomised, placebo controlled trial of lactic acid bacteria and bifidobacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 years and over admitted to hospital and receiving antibiotics
Swansea University (UK)0 个研究点目标入组 2,974 人开始时间: 2009年7月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,974
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. People aged greater than or equal to 65 years, either sex
- •2. Admitted to hospital without diarrhoea
- •3. Have been exposed to one or more antibiotics within the last 7 days or are about to start antibiotic treatment
排除标准
- •1. People with known immunosuppressive disorder, prosthetic heart valve or active inflammatory bowel disease (the latter defined as requiring specific treatment in the past 12 months)
- •2. Acute pancreatitis (defined as abdominal pain with serum amylase or lipase concentration greater than or equal to three times the institutional upper limit of normal)
- •3. Jejunal tube in-situ and/or jejunal feeding (as documented in the clinical/nursing records)
- •4. Likely impaired splanchnic perfusion: any past or current abnormality or disease affecting the mesenteric arteries (as documented in the clinical records)
- •5. Severe illness requiring care in either a high dependency or intensive care unit (but not planned admission to these facilities for observation only, e.g., after cardiac surgery)
- •6. People with a previous history of adverse reactions to probiotics
- •7. Informed consent not granted by patient or their carer(s)
研究者
相似试验
进行中（未招募）
1 期
A multicentre, randomised, placebo controlled trial of lactic acid bacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 years and over admitted to hospital and receiving antibiotics (06/39/02)AAD is diarrhoea occurring in association with antibiotic treatment without an alternative cause. It occurs typically 2-8 weeks after exposure to antibiotics. The frequency of AAD varies markedly between studies according to risk factors such as exposure to broad-spectrum antibiotics, nosocomial infections and host factors such as age, health status, gender.MedDRA version: 9.1 Level: PT Classification code 10064065 Term: Prophylaxis against diarrhoeaEUCTR2007-002876-32-GBniversity of Wales Swansea2,974
尚未招募
不适用
ebulised heparin for lung injuryPatients with or at risk of developing Acute Respiratory Distress Syndrome.Respiratory - Other respiratory disorders / diseasesACTRN12612000418875St.Vincents Hospital/Institute256
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-DEniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-PTniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 19.1Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-BEniversité catholique de Louvain (UCL)296